• S Schuh, D W Johnson, D Stephens, S Callahan, P Winders, and G J Canny.
• Divisions of Emergency, Clinical Pharmacology, Chest, and Clinical Epidemiology, the Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
• J. Pediatr. 1999 Jul 1; 135 (1): 22-7.

ObjectiveIn children with mild acute asthma, to compare treatment with a single dose of albuterol delivered by a metered dose inhaler (MDI) with a spacer in either a weight-adjusted high dose or a standard low-dose regimen with delivery by a nebulizer.Study DesignIn this randomized double-blind trial set in an emergency department, 90 children between 5 and 17 years of age with a baseline forced expiratory volume in 1 second (FEV1 ) between 50% and 79% of predicted value were treated with a single dose of albuterol, either 6 to 10 puffs (n = 30) or 2 puffs (n = 30) with an MDI with spacer or 0.15 mg/kg with a nebulizer (n = 30).ResultsNo significant differences were seen between treatment groups in the degree of improvement in percent predicted FEV1 (P =.12), clinical score, respiratory rate, or O2 saturation. However, the nebulizer group had a significantly greater change in heart rate (P =.0001). Our study had 93% power to detect a mean difference in percent predicted FEV1 of 8 between the treatment groups.ConclusionIn children with mild acute asthma, treatment with 2 puffs of albuterol by an MDI with spacer is just as clinically beneficial as treatment with higher doses delivered by an MDI or by a nebulizer.

19 keywords...

hide…